Tr1X

About

Tr1X Bio is a clinical-stage biotechnology company based in San Diego, California. The company specializes in developing innovative regulatory T cell-based products aimed at curing autoimmune and inflammatory diseases. Tr1X's mission is to shift the treatment paradigm from management to cure, utilizing scientific advancements to create impactful medicines. Founded by experts in the field, Tr1X is at the forefront of cellular immunotherapy. The company is working on a pipeline of off-the-shelf allogeneic cell therapies that convert CD4+ T cells from healthy donors into Treg-like cells, mimicking the function of naturally occurring Type 1 regulatory T (Tr1) cells. Additionally, Tr1X is exploring CAR-Treg cell therapies to enhance the therapeutic potential of Treg cells. In January 2024, Tr1X completed a $75 million Series A financing round, supported by notable investors. The company is committed to addressing the needs of patients with autoimmune and inflammatory diseases through its advanced therapeutic approaches.